Please contact us for more information or to learn if you are eligible to participate.
This is a nonrandomized, single arm feasibility study with the primary goal of evaluating the safety profile of the combination of atezolizumab and bevacizumab in patients with advanced/metastatic HCC with Child-Pugh B7 and B8 liver disease who have received no prior systemic therapy.
Dr. Lee C. Drinkard
Edgar Lopez Pacheco
Kristen Spencer, DO, MPH Rutgers Cancer Institute of New Jersey
Type of Trial